Please assess the completion status of the following clinical trial:

Trial Title: HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV uninfected on the basis of a negative HIV Rapid Test, EIA or Western blot, and a negative HIV-1 RNA assay~* Possible non-occupational exposure to HIV-1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure.~* Able to understand the study procedures and willing to sign informed consent~Exclusion Criteria:~* Any active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures.~* Pregnancy.~* Chronic hepatitis B infection, diagnosed by either positive serum HBsAg or positive serum HBV DNA; or prior lamivudine therapy for hepatitis B.~* Creatinine clearance less than 50 mL/min as calculated by Cockcroft-Gault formula.~* Unwillingness to participate in study procedures, including Mental Health referral and intervention.~* Known intolerance or allergy to tenofovir DF, emtricitabine or raltegravir.~* Use of prohibited concomitant medication: dilantin, phenobarbital and rifampin which cannot be used with raltegravir.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: OTHER): TRUVADA

Based on this trial design, predict the completion outcome and termination type (if applicable).